SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting

PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024, in Chicago, IL. BOXR1030 is a next-generation GPC3-targeted CAR T-cell therapy enhanced with a transgene encoding GOT2, a critical enzyme involved in cellular